Patent · US Active

Prodrug compound of levosimendan, preparation method and use thereof

US11591299B1 · kind B1 · utility

0Cited by

0References

8Claims

0Family size

Assignee

Beijing Chenguang Tongchuang Pharmaceutical Research Institute Co., Ltd. · CN

Inventors

Shaolin Huang · Liuji, CN
Changbin Guo · Beijing, CN
Wei Li · Laishui, CN
Liang Ma · Fryeburg, US
Qingjuan Yang · Beijing, CN
Pengfei Song · Beijing, CN
Jingwang Fan · Beijing, CN
Xiaosong Mao · Beijing, CN

Key dates

Filing date	Mar 15, 2022
Grant date	Feb 28, 2023
Priority date	—
Expiry date	Mar 15, 2042

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D237/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

The invention relates to a prodrug compound of levosimendan as shown by the formula below, and solvates, hydrates, N-oxides, stereoisomers, and pharmaceutically acceptable salts thereof, wherein each of Ra and Rb is selected from hydrogen or C1-C6 alkyl; Rp is selected from a basic group containing N atom or an acidic group containing carboxyl group, phosphate group, sulfate group, and sulfonate group. The prodrug compound overcomes the defects of levosimendan such as poor water solubility, and has an ideal pharmacokinetic profile and excellent prospects for medicament development.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.